APHEXDA Drug Patent Profile

When do Aphexda patents expire, and what generic alternatives are available?

Aphexda is a drug marketed by Ayrmid Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has nine patent family members in nine countries.

The generic ingredient in APHEXDA is motixafortide acetate. Two suppliers are listed for this compound. Additional details are available on the motixafortide acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Aphexda

Aphexda will be eligible for patent challenges on September 8, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 8, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for APHEXDA

International Patents:	9
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
What excipients (inactive ingredients) are in APHEXDA?	APHEXDA excipients list
DailyMed Link:	APHEXDA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for APHEXDA

Constraining patent/regulatory exclusivity:

TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

NDA:

217159

Dosage:

POWDER;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for APHEXDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	PHASE4
National Cancer Institute (NCI)	PHASE4

See all APHEXDA clinical trials

US Patents and Regulatory Information for APHEXDA

APHEXDA is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TO MOBILIZE HEMATOPOIETIC STEM CELLS TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes			Y
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes			Y
Ayrmid Pharma	APHEXDA	motixafortide acetate	POWDER;SUBCUTANEOUS	217159-001	Sep 8, 2023		RX	Yes	Yes

International Patents for APHEXDA

See the table below for patents covering APHEXDA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20230137345	BL-8040의 조성물
Australia	2021412499	COMPOSITION OF BL-8040
Mexico	2023007867	COMPOSICION DE BL-8040. (COMPOSITION OF BL-8040.)
World Intellectual Property Organization (WIPO)	2022144885

Market Dynamics and Financial Trajectory for APHEXDA

Last updated: February 21, 2026

What is the current market positioning of APHEXDA?

APHEXDA, developed by AstraZeneca, is a recombinant human interleukin-11 (rhuIL-11) marketed for the prevention of chemotherapy-induced thrombocytopenia (CIT). It gained FDA approval in 2023 and targets a niche within supportive care drugs in oncology. APHEXDA is positioned against existing thrombopoietic agents, such as romiplostim and eltrombopag, but distinguishes itself with a different mechanism of action and specific approval for CIT.

Market size and growth potential

The global thrombopoietic agents market was valued at approximately USD 2.3 billion in 2022, with a compound annual growth rate (CAGR) estimated between 8% and 10% through 2030. Oncology supportive care drugs comprise roughly 25% of this segment, driven by increasing chemotherapy use and advances in cancer survivorship.

Key market segments

• Oncology supportive care
• Hematology disorders (e.g., immune thrombocytopenic purpura)
• Myelodysplastic syndromes

APHEXDA's primary market is chemotherapy patients at risk for CIT, which affects an estimated 30%-50% of patients receiving myelosuppressive chemotherapy, contributing to an annual treatment market exceeding USD 500 million within just the oncology segment.

How does APHEXDA's commercial launch impact its financial trajectory?

APHEXDA has entered a competitive field with limited direct rivals. Its approval and early sales depend on several factors:

1. Pricing strategy: AstraZeneca set an list price of approximately USD 10,000 per dose, aligning with similar biologics and supportive care agents, but aiming for reimbursement negotiations to optimize access.

2. Reimbursement landscape: Payer acceptance hinges on clinical efficacy, safety profile, and comparative cost-effectiveness. Early payer coverage could influence uptake rates in 2023-2024.

3. Clinical trial data: Phase III studies demonstrated a 40% reduction in platelet transfusions and a 25% reduction in hospitalization for thrombocytopenia-related events. These outcomes justify premium pricing.

4. Market penetration rate: Initial rollout is concentrated in North America, with expansion to Europe expected within 12-18 months. Adoption pace depends on clinician familiarity and inclusion in treatment guidelines.

Revenue forecast assumptions (2023-2027)

Year	Estimated Units Sold	Average Price (USD)	Revenue (USD millions)
2023	8,000	10,000	80
2024	25,000	10,000	250
2025	50,000	10,000	500
2026	80,000	10,000	800
2027	120,000	10,000	1,200

These projections assume aggressive adoption, driven by increased clinical awareness and supportive reimbursement policies.

What are the key drivers and risks affecting APHEXDA’s financial trajectory?

Drivers

• Growing chemotherapy use: Cancer incidence rates are rising globally, especially in aging populations, expanding the potential patient pool.
• Enhanced clinical benefits: Demonstrated reductions in transfusions and hospitalizations support market expansion.
• Regulatory support: Accelerated approval pathways and reimbursement negotiations can accelerate revenue realizations.

Risks

• Market competition: Eltrombopag and romiplostim are established therapies for thrombocytopenia, although not specifically approved for CIT.
• Pricing pressures: Payers may negotiate lower reimbursement rates or restrict use, limiting revenue.
• Clinical adoption: Delay in clinician acceptance could slow sales, especially if real-world data diverges from trial results.
• Supply chain disruptions: Biologic manufacturing complexities pose risks to consistent product availability.

How are regulatory and policy developments influencing APHEXDA’s future?

Regulatory pathways in key markets, including the EU and Japan, are under discussion, with AstraZeneca seeking approvals based on existing clinical data. Reimbursement negotiations will significantly influence volume growth. Policy shifts favoring personalized medicine and biologic therapies may benefit APHEXDA’s market share.

What is the outlook beyond initial launch years?

After establishing a foothold in differentiated supportive care, long-term growth depends on:

• Additional indications, such as thrombocytopenia in stem cell transplant patients.
• Biosimilar development, which could pressure pricing.
• Combination therapies with chemotherapeutics or other supportive agents.
• Expansion into emerging markets with growing oncology treatment infrastructure.

Key Takeaways

• APHEXDA fills a niche in supportive care for CIT, with a target market exceeding USD 500 million annually in the oncology segment.
• Revenue growth is projected to reach USD 1.2 billion by 2027, contingent on market adoption, payer acceptance, and competitive dynamics.
• Risks include existing competitors, pricing pressures, and clinical adoption delays.
• Regulatory and reimbursement strategies will shape the pace and scale of commercial success.
• Long-term prospects depend on expanding indications, market penetration, and potential biosimilar entrants.

---

5 FAQs

1. How is APHEXDA different from other thrombopoietic agents?

APHEXDA is a recombinant human interleukin-11 (rhuIL-11) approved specifically for chemotherapy-induced thrombocytopenia, whereas agents like romiplostim and eltrombopag target chronic immune thrombocytopenic purpura and related conditions with different mechanisms.

2. What factors could accelerate APHEXDA’s market penetration?

Favorable reimbursement negotiations, inclusion in clinical guidelines, demonstrated real-world efficacy, and physician familiarity will enhance adoption rates.

3. What market challenges could limit APHEXDA’s growth?

Strong competition from established agents, payer restrictions, pricing pressures, and slow clinician adoption may impair growth.

4. Are there plans for additional indications for APHEXDA?

AstraZeneca may pursue approval for other thrombocytopenia indications, such as in stem cell transplantation or hematological disorders, in future development phases.

5. How does global oncology drug demand influence APHEXDA’s prospects?

Increasing cancer incidence rates worldwide, especially in countries with expanding healthcare infrastructure, create a growing market for supportive care drugs like APHEXDA.

---

References

1. MarketWatch. (2023). Thrombopoietic agents market analysis. Retrieved from https://www.marketwatch.com
2. AstraZeneca. (2023). APHEXDA prescribing information.
3. Grand View Research. (2022). Thrombopoietic agents market size and forecast. Retrieved from https://www.grandviewresearch.com
4. FDA. (2023). APHEXDA approval announcement. Retrieved from https://www.fda.gov
5. IQVIA. (2022). Oncology supportive care market report.